Sarcopenia Market Trends, Market Share & Size, Market Research Report 2030

 Sarcopenia is a condition which is characterized by loss of muscle mass, muscle strength and functional muscle impairment with ageing. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases.

DelveInsight's "Sarcopenia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Sarcopenia , historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geography Covered

·         The United States

·         EU5 (Germany, France, Italy, Spain, and the United Kingdom)

·         Japan

Study Period: 2017-2030

View report: https://www.delveinsight.com/sample-request/sarcopenia-market

Sarcopenia Epidemiology  

Current definitions of sarcopenia are only newly developed and still not entirely accepted. Reported prevalence rates of sarcopenia vary significantly due to differing definitions, tools of diagnosis, and patient populations. Estimates range from 10% in individuals >65 years of age, rising to 30% in men over 80.

The Sarcopenia epidemiology division provide insights about historical and current Sarcopenia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Sarcopenia Drug Chapters

Research is underway to identify therapeutic targets and develop a curative therapy for the treatment of sarcopenia. But, the current sarcopenia pipeline is poor with very few industry-funded trials. Some of the potential candidates are elaborated below.

Drug chapter segment of the Sarcopenia report encloses the detailed analysis of Sarcopenia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Sarcopenia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Sarcopenia Market Outlook

Early recognition and intervention is the key to improved outcomes in patients with sarcopenia. Screening patients for impairment in their physical function and activities of daily living (ADLs) should be a routine part of healthcare visits for the elderly.

Currently, there are no agents for the treatment of sarcopenia that have been FDA approved. Nutritional supplementation, resistance training, exercise, vibrational therapy constitute the treatment space for sarcopenia. Compared with singular interventions, combined interventions, including comprehensive exercise‐based treatment interventions, such as resistance training and nutritional intervention, are effective for improving sarcopenia and are recommended.  

The Sarcopenia market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Sarcopenia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

According to DelveInsight, Sarcopenia market in 7MM is expected to change in the study period 2017-2030.

Download full report: https://www.delveinsight.com/sample-request/sarcopenia-market

Comments

Post a Comment

Popular posts from this blog

Beta-thalassemia Market Poised for Significant Growth with Novel Therapies and Rising Prevalence

The Beta-thalassemia market is set to experience remarkable growth in the coming years, driven by the increasing prevalence of the condition and the anticipated launch of innovative therapies. Leading players in the pharmaceutical and biotech industries, including Acceleron Pharma, Agios Pharmaceuticals, Bluebird Bio, and CRISPR Therapeutics, are working diligently to address unmet medical needs and expand treatment options. Download our sample pages @ https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr Market Dynamics and Key Drivers Beta-thalassemia, a hereditary blood disorder caused by mutations in the HBB gene, results in reduced or absent synthesis of beta-globin chains in hemoglobin. This condition affects millions worldwide, with significant prevalence in regions such as the United States, Europe, and Asia. Recent advancements in diagnostics and a heightened focus on genetic counseling have contribute...
Read more

Growth of the Candidemia Market: Drivers, Developments, and Future Outlook (2024-2034)

Candidemia , a bloodstream infection caused by Candida species, poses significant health challenges, particularly among individuals with weakened immune systems. The global candidemia market is projected to experience a compound annual growth rate (CAGR) of 3.16% from 2024 to 2034. citeturn0search0 Market Drivers: Increasing Incidence: The rising number of immunocompromised patients, including those with HIV/AIDS, cancer, or organ transplants, has led to a higher prevalence of candidemia. Advancements in Diagnostics: The adoption of advanced diagnostic techniques, such as molecular assays and biomarker identification, facilitates swift and accurate detection of candidemia, enabling timely intervention and improved patient outcomes. Innovative Therapeutics: The development of novel antifungal medications and immune-based therapies offers enhanced efficacy and reduced adverse effects, contributing to market growth. To know more about candidemia market drivers, visit https://www.delvei...
Read more

Unlocking the Facts: C-Met Mutated Non-Small Cell Lung Cancer Epidemiology, Market Trends, and Leading Players

What is C-Met Mutated Non-small Cell Lung Cancer ? C-Met (also known as MET) is a gene that codes for a protein called the "hepatocyte growth factor receptor" (HGFR) or c-Met receptor. This receptor plays a crucial role in regulating cell growth, survival, migration, and invasion. When the c-Met gene is mutated, it can lead to the abnormal activation of signaling pathways that promote cancer development and progression. How is C-Met Mutated Non-small Cell Lung Cancer epidemiology segmented? C-Met Mutated Non-small Cell Lung Cancer epidemiology is segmented as C-Met Mutated Non-small Cell Lung Cancer Total Incident Cases, Age-specific C-Met Mutated Non-small Cell Lung Cancer cases, Gender-specific C-Met Mutated Non-small Cell Lung Cancer Cases, Stage-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, Type-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, and Total Treated C-Met Mutated Non-small Cell Lung Cancer Cases. What is the C-Met Mutated...
Read more